Entities

Sungwook Moon (문성욱) was appointed head of SK Networks Americas in March2025 according to the parent’s official annual report. The appointment concerns the US investment subsidiary formerly named HICO Capital, not the separate HICO Ventures fund-manager roster. Current tenure and an authentic portrait have not been independently verified; no same-name person in government or another investment firm is assumed.

Changho Jin (진창호) was appointed head of HICO Capital, SK Networks’ US corporate investment subsidiary, on23 May2024 according to the parent’s official filing. The parent’s 2025 annual report states that he was replaced in March2025 after the vehicle was renamed SK Networks Americas. This profile identifies that source-qualified corporate executive and does not assume identities or portraits of same-name professionals.

Nkechi Iregbulem is an investor and technology professional with experience in early-stage investing and a published Clear Ventures deep-tech fellowship biography. She appeared as a HICO Ventures investor in a November2025 event listing and remains named in HICO’s website people menu, but the linked profile is unavailable. Her current HICO role and tenure are unconfirmed; no HICO institutional portfolio check is inferred as her personal investment. Her own May2024 public announcement explicitly reports an angel investment in Neros, and her March2025 retrospective states that she invested since its pre-seed. This personally sourced investment is distinct from any HICO employer participation; exact ticket and payment day remain unpublished.

Gina Moon is a Yale School of Management MBA student in the class of2027. Yale identifies her pre-MBA position as associate at HICO Ventures and her earlier work as manager of global investment at SK Networks. She studied business administration and Chinese at Hanyang University. Her HICO affiliation is historical; the firm’s older website listing does not establish current employment.

Hardik Mittal is a partner at HICO Ventures. Raised in New Delhi and educated in electrical engineering at UCLA, he previously worked in product marketing for timing products at Texas Instruments before joining SK Networks’ investment business. His published experience includes direct startup investing and fund investments across frontier technology.

Carlos Trenchs co-founded Aldea Ventures and is identified as its Partner by his current own Masia profile, where he also serves as Co-Founder and Chairman. CNMV lists Carlos Trenchs Sainz de la Maza as an Aldea statutory director. He previously built CaixaCapitalRisc and teaches venturecapital/corporateventuring atESADE. His personal/predecessorinvestmenthistory isnotallocated toAldea directchecks.

Oversees fund accounting, financial operations, and performance reporting across Aldea's platform. Adrià is responsible for Aldea's financial operations, fund accounting, and reporting infrastructure, ensuring accuracy, consistency, and transparency across the firm's funds and portfolios. He works closely with the investment and operations teams to support disciplined execution and institutional-grade reporting for Aldea's LP base. Prior to joining Aldea, Adrià worked in portfolio management and financial analysis roles at Maverick SMF (London), and previously held analytical positions at Investec and the University of Oxford. His background spans fund operations, performance analysis, and financial controls across institutional investment environments. Adrià holds a Master's degree in Finance from Bentley University.

Leads Aldea's data infrastructure, analytics, and portfolio intelligence. Alina oversees the design and development of Aldea's data and analytics platform, supporting investment decision-making, portfolio monitoring, and fund-level reporting across the firm. Her work sits at the intersection of venture capital, data engineering, and financial modeling, enabling a more systematic and insight-driven investment process. Her background combines academic research in venture capital with hands-on experience building data pipelines, analytical frameworks, and performance models for alternative investment strategies. At Aldea, she works closely with the investment team to translate qualitative conviction into structured analysis across managers, companies, and portfolios. In parallel with her work at Aldea, Alina teaches Venture Capital at ESADE and Business Analytics at the University of Barcelona, reflecting her strong grounding in both theory and applied practice.

Leads sourcing, diligence, and portfolio engagement across Aldea's investment platform. Gabrielle brings over a decade of experience sourcing and evaluating early-stage technology investments, with a particular focus on founder quality, market dynamics, and execution risk. She works closely with Aldea's partners across fund and direct strategies, supporting investment decisions from initial conviction through portfolio engagement. Prior to Aldea, Gabrielle held operating and investment-facing roles across Europe and the U.K. She previously served as COO at Learn Amp, where she supported the company's growth and product expansion, and earlier worked on international expansion initiatives at Mitiga Solutions, a deep-tech company operating across multiple geographies. At Aldea, Gabrielle is a core member of the investment team, partnering with managers and founders throughout the lifecycle and contributing to portfolio construction, diligence processes, and ongoing support. She holds a degree from the University of Cambridge and an Executive MBA from IESE Business School.

Leads operations, investor relations, and institutional execution across Aldea's platform. Daniela brings over 13 years of experience across investment banking and alternative investments, with deep expertise in investor relations, capital formation, and firm-wide operations. She is responsible for translating Aldea's strategy into disciplined execution across funds, LP relationships, and institutional processes. Prior to joining Aldea, Daniela held roles spanning M&A, capital markets, and investor relations across London and Milan. She previously led Investor Relations at a Barcelona-based alternative investment firm, working closely with institutional and family office investors across Europe. At Aldea, Daniela partners closely with the investment team to support fund launches, LP engagement, reporting, and governance, ensuring a high standard of transparency, rigor, and operational excellence as the platform scales. Daniela holds a BA in International Economics and Management and an MSc in Finance from Bocconi University, both cum laude.

Leads direct investments backing founders building frontier technologies, while serving across Aldea's investment committee and fund platform. Andrew focuses on technically complex, founder-led businesses scaling from early conviction to global impact. He brings a founder-first perspective shaped by operating, investing, and building across both the U.S. and Europe. Before Aldea, Andrew was a Partner at Alumni Ventures, where he made more than 50 investments and worked through a period of significant scale as the firm grew from approximately $500 million to $1.5 billion in assets under management. Earlier, he was an investor at Mithril Capital—founded by Peter Thiel—and at GCM Grosvenor, where he helped manage a $2 billion emerging manager mandate on behalf of the Teachers Retirement System of Texas. His investment experience spans category-defining technology businesses across compute, neurotechnology, robotics, and infrastructure. Having founded and operated companies himself, Andrew partners closely with founders at moments of technical and organizational inflection. He began his career as a CPA at Ernst & Young and holds an MBA from Columbia Business School.

Leads fund strategy, manager selection, and portfolio construction across Aldea's integrated investment platform. Alfonso brings over two decades of experience across venture capital and company building, with a focus on portfolio construction, manager evaluation, and long-term capital allocation. His work centers on identifying emerging managers early and building diversified portfolios designed to perform across cycles. Prior to co-founding Aldea, Alfonso was employee #1 at Nauta Capital, where he helped scale the firm from its first €8m fund to over €500m in assets under management. During this period, he participated in more than 65 investments across Europe and the U.S., gaining deep exposure to fund formation, portfolio dynamics, and cross-border venture ecosystems. Earlier in his career, Alfonso served as CFO/COO of a transatlantic technology scale-up, giving him an operator's perspective on growth, capital efficiency, and organizational scaling. He works closely across Aldea's investment activities, contributing both to fund strategy and direct investment decisions. Alfonso holds a BBA and an MBA from ESADE Business School.

Leads Aldea's long-term platform strategy and institutional partnerships, ensuring alignment across funds, managers, and investors. Gonzalo brings more than three decades of experience spanning law, investment banking, entrepreneurship, and long-term capital formation. He focuses on building durable investment platforms grounded in trust, governance, and multi-generational alignment. Before founding Aldea, Gonzalo held senior roles across legal, advisory, and financial institutions, including Cuatrecasas, Gómez-Acebo & Pombo, and GBS Finance. His career has been shaped by working closely with founders, families, and institutional investors navigating complex ownership structures and long-horizon decisions. In parallel with his investment work, Gonzalo has served on multiple boards, including Inversiones y Servicios Publicitarios, a family-owned holding company operating across 12 countries. These experiences inform Aldea's emphasis on disciplined governance, institutional rigor, and partnership built over time. Gonzalo holds a Law degree from the University of Barcelona and completed Columbia Business School's Advanced Management Program.

Samuel Kim is managing partner of HICO Ventures and managing member of HICO Management LLC, as confirmed by its March2026 SEC filing. His career spans investment banking, cross-border corporate development and venture investing. He previously headed SK Networks’ US investment vehicle, then HICO Capital, and was replaced in that holding-company role on 23 May2024; that historical change does not end his separately documented manager affiliation.

Aldea Ventures is a Barcelona investment platform backing technically ambitious companies across Europe and the UnitedStates. Its current thesis spans AI and computing infrastructure, software-operated expert workflows, robotics and machine perception, programmable biology, energy systems and industrial capabilities. The legal manager is Aldea Ventures, SGEIC, S.A., Spanish NIF A01636133, CNMV registration215. Its model combines partnerships with early-stage specialist venture funds and direct company investments; the current website explicitly distinguishes companies directly backed by Aldea from companies backed through seed-fund partners. Those indirect ecosystem companies are not automatically Aldea direct investments, and a partner’s prior investment history is not assigned to the firm. The current own public operating directory names seven people; CNMV additionally identifies co-founder CarlosTrenchs among statutory directors, independently corroborated by his current Masia bio. Six actual registered investment vehicles include the A/B forms of AldeaTechFundI andII, AldeaOpportunityFundI and MasiaCollectiveSeedFundI. MasiaCapitalSL is a separately identified appointed advisory representative, not merged with the Aldea manager. No unverified target, aggregate strategy corpus or regulatory asset value is allocated as the closed size of each parallel vehicle. Automata’s October3,2023 issuer announcement confirms Aldea as a returning participant in its actual USD40M growth financing; individual check amount remains unpublished.

HICO Ventures is the Silicon Valley venture investment business managed by HICO Management LLC, an exempt reporting adviser with SEC CRD 328878. Its parent is SK Networks Americas LLC, formerly HICO Capital LLC; the corporate holding vehicle and this fund manager are distinct. HICO invests in early-stage artificial intelligence, AGI infrastructure and middleware, digital assets and frontier technologies across geographies. Its published initial-check strategy of USD250,000–1 million is a strategy range, not an amount assigned to every investment. Samuel Kim is managing partner and the legal manager’s managing member; Hardik Mittal is a partner. Gina Moon’s affiliation is historical, confirmed as pre-MBA employment by Yale, and the website-listed Nkechi Iregbulem affiliation is qualified because her linked profile is unavailable and current employment is unconfirmed. Current SEC filings identify HICO Ventures I LP and a Bow-HICO feeder with separate legal general partners. SK Networks announced an initial joint-fund close at the end of 2023; the exact date and total committed capital are undisclosed. A USD50 million initial offering target with zero sold in the initial Form D is not a confirmed fund close. Actual issuer-confirmed investments include Final Round AI and Poetiq. Investment-manager portfolio relationships are not retroactively attributed to its later-formed funds when the original corporate subscriber was TenX/HICO Capital.

SK Networks Americas LLC is the wholly owned US corporate investment arm of SK Networks. Incorporated in Delaware on 15 May 2020 as TenX Capital LLC, it changed its legal name to HICO Capital LLC on 26 July 2022 and to SK Networks Americas LLC on 16 January 2025. Its Silicon Valley venture investments include computer-vision company Standard Cognition (Standard AI), agricultural autonomy company Sabanto and advanced-materials company MycoWorks. The historical HICO Capital corporate vehicle is the same entity represented here; it is distinct from subsidiary HICO Management LLC, which manages the HICO Ventures investment business and legal private funds. Parent SK Networks and this subsidiary are not duplicate investors in the same transaction. Samuel Kim formerly headed the corporate vehicle, followed by Changho Jin and Sungwook Moon according to official filings. The latest documented appointment is March 2025; a complete current employee roster and current executive tenure have not been established. Its genuine current SK Networks Americas wordmark is published on the parent’s company page. Historical parent investment programs and subsidiary commitments are not asserted as closed LP funds.

Giovanna Dossena is identified as founder on the Milan Add Value srl website. Its published biography describes her background in investment management and academic business research. The current AVM SGR team independently identifies her as principal of AVM SGR and AVM Associati, with a career in private equity and business advisory and a University of Bergamo professorship. These outside affiliations are source-attributed; no automatic AVM manager fund or personal check is attached to Add Value.

Add Value srl is a Milan investment company that describes its activities as M&A, private equity and venture capital through club deals. Its published technology interests include artificial intelligence, IoT, industrial robotics, photonics, aerospace and security. It supports business growth, build-ups and buy-outs through direct investments or dedicated SPVs. The exact own-site legal identifiers are VAT/tax number08406060965 and Milan REAMI-2023869. The firm publicly identifies Giovanna Dossena as founder and describes her AVM background. Its prospective investment-fund policy and corporate share capital do not establish an external LP-backed fundraising close. This entity is distinct from Verona software companyAddValue ataddvalue.it and the Belgian recruitment firmataddvalue.eu. Neurala’s2021 financing names an AddValue investor; a dated2020 press report associates AVM-group AddValue with a Neurala club deal, but no direct primary legal/domain bridge has yet confirmed that the Milan entity was the exact subscriber. That financing is therefore not assigned to this profile. Current unnamed staffing, undisclosed SPVs and check amounts are not inferred.

Oxford Endovascular Limited is a University of Oxford medical-device spinout founded in 2015. It develops OxiFlow, an origami-inspired nitinol flow-diverting stent for intracranial aneurysms, designed to improve placement, vessel conformity and blood-flow diversion. Its published leadership includes chairman Chas Taylor, clinical director James Byrne and technology director Zhong You. Co-founder Mike Karim is a former CEO; his current personal biography supersedes the older company directory, and the successor is unverified. Announced equity financing includes GBP2.5 million in May2018, a GBP7.5 million SeriesA in April2021 (also described as USD10 million, the same raise), and GBP8 million SeriesA+ in May2024. Separate support includes Horizon2020 grant859001, with a contracted EU contribution of EUR2,962,979.95, an awarded GBP350,000 InnovateUK SmartGrant and EUR500,000 from EITHealth’s 2020 grant-for-options rescue instrument. Grant awards and contracts do not establish payment. The May2024 release describes preparations for first-in-human studies; current clinical and regulatory status is not confirmed by the reviewed sources.

Chas Taylor is listed as chairman by Oxford Endovascular. His published company biography describes an entrepreneurial medical-device career that includes founding and leading Veryan, Novate and MedNova, fundraising and exits. His work spans device development, regulatory planning and commercialization. He is distinct from Charles Taylor, the existing Ozlo Sleep co-founder.

James Byrne is listed as Oxford Endovascular’s clinical director. He is a professor of neuroradiology and consultant neuroradiologist with extensive experience treating brain aneurysms, training physicians and developing and testing device prototypes. The company describes his clinical background as contributing to its neurovascular device development.

Mike Karim co-founded and previously led Oxford Endovascular. His older company biography describes international medical-device experience in leadership, sales, marketing, fundraising and bringing devices to market. His current personal consulting website and Synapto Ventures biography explicitly describe the Oxford Endovascular CEO role in the past tense. The transition date and successor are not verified; the older company directory is not treated as evidence of his current CEO status.

Zhong You is listed as Oxford Endovascular’s technology director. He is a professor of engineering science whose research includes origami structures and minimally invasive medical devices. His company biography describes Wellcome Trust Centre of Excellence support for prototype medical-device development.

Andreas Munk Holm is a Venture Partner at Isomer Capital working with emerging European venture managers. He co-founded The European VC, an industry podcast and network that also organises limited-partner syndicates. The advisory affiliation is distinct from automatically attributing personal company investments.

David Cruz e Silva is a Venture Partner at Isomer Capital supporting research into emerging European venture managers. He co-founded The European VC, which operates a venture-industry podcast, network and limited-partner syndicates. These separate activities do not establish personal checks into each Isomer portfolio company.

Philip Walker is a Venture Partner at Isomer Capital working on its Swiss and DACH presence. He previously was a Partner at Obviam and worked in emerging-market venture capital through Forestart and NXT-ALT.

Charles Schrager is a Venture Partner at Isomer Capital with experience as a limited partner, general partner, director and technology executive. He previously was a Partner at Penta Capital and a Managing Director in Credit Suisse’s financial-institutions investment-banking group.

Hiroshi Baba is a Tokyo-based Venture Partner at Isomer Capital supporting Japanese limited partners’ innovation programmes. He also advises the Japan Professional Football League. Previously he led NTT Docomo’s corporate venture-capital business and its international expansion.

Pascal Isbell is an Investment Adviser and investment-committee member at Isomer Capital. He has built an angel-investment portfolio, co-founded Lancea Partners in 2005 and previously worked in technology, media and telecommunications investment banking in the United States and Europe. Isomer’s card heading spells Pascall, while the biography, portrait filename and own professional-profile URL consistently use Pascal.

Marloes Dellemann is Office Manager at Isomer Capital, supporting business operations, events and the investor community. She has also written and published a Dutch children’s book.

Laura Corrigan is an Analyst at Isomer Capital supporting sourcing, diligence and investment execution across funds, co-investments and secondaries. She also coordinates ecosystem initiatives including the European VC Awards. Her earlier work involved early-stage technology businesses and a UK investor community.

Kevin D’Souza is an Associate at Isomer Capital working across fund investments, co-investments and secondaries. Previously he invested at Boldcap, evaluating AI seed opportunities across India and the United States, and worked on fund underwriting, direct investments and secondaries at TrueBridge Capital Partners.

Nicola Fleetwood is Head of Finance at Isomer Capital. She oversees accounting, corporate and fund reporting, cash management and Luxembourg operations. Her earlier career includes other finance positions in private equity. A separate 2025 legal Team LLP ownership disclosure is not treated as an independently closed investment fund.

Omolade Adebisi is a Principal at Isomer Capital focused on European venture-fund and company secondaries. Previously she helped establish a venture-capital secondaries fund in the Middle East, worked at Coller Capital and started her banking career at Citi. She also founded a marketplace startup. Her own professional profile uses Omolade Rachel Adebisi.

Michael Joyce is a Principal at Isomer Capital working across fund investments, secondaries and company co-investments, with data-analysis responsibilities. He previously served as an Investment Director at Cambridge Associates and researched emerging technologies at Fidelity Investments.

Thomas Schneider is a Partner and investment-committee member at Isomer Capital. He leads fundraising and investor relations and contributes to manager research in continental Europe, particularly France and Italy. Previously he led Russell Investments’ Southern Europe business. UK legal filings identify Thomas Archibald Oscar Schneider.

Chloe Dagnell is a Principal at Isomer Capital, responsible for its pipeline of new venture-fund managers and co-management of a separate vehicle for one limited partner. She also researches climate investment and ESG. Her earlier consulting work included supporting a World Bank accelerator and a UK government technology-for-good fund.

Cochlear Limited is an Australian medical-technology company that develops, manufactures and commercializes implantable hearing systems. Its products include Nucleus cochlear implants and external sound processors, alongside Baha and Osia bone-conduction systems, connected applications and services supporting recipients over the life of their implants. Headquartered in Sydney, the company began operations in 1981 and is listed on the Australian Securities Exchange. It conducts hearing research and develops technology with clinical and industry partners; its investment in OculAudio Corti AS supported research into an eyeglass-based microphone accessory for cochlear implant users.

Former chief executive of technology and media businesses, experienced in digital transformation and corporate governance.

Medtech executive with international management and commercial experience, including more than twenty years at Johnson & Johnson.

Otolaryngologist directing clinical strategy while maintaining a cochlear-implant surgical practice; Cochlear describes a two-thirds-time commitment.

Physician and research leader experienced in clinical medicine, scientific innovation and healthcare commercialization.

Healthcare and consumer-technology executive with extensive international leadership experience at Philips.

Chris Wade co-founded Isomer Capital and is a Partner. He co-leads fund investing, leads company co-investments and manages Japanese limited-partner relationships and the corporate-investor programme. Previously he was a technology entrepreneur and a venture partner with Octopus Ventures and Entrepreneur First. UK legal filings identify Christopher John Wade. He is a different person from Patient Square Capital’s chief financial officer Chris Wade.

Experienced chair and director across financial services, resources, health insurance and infrastructure.

Medical-device and pharmaceutical executive responsible for product planning, commercialization, market access, brand and communications.

Engineer with manufacturing and regional leadership experience at Cochlear; appointed CEO and president in January 2018.

Leads product industrialization, procurement, manufacturing and logistics, with extensive operations experience.

Leads hearing-technology research, development, business development, quality and regulatory responsibilities.

Leads global information-technology strategy and systems, with prior digital-services experience at Ventia.

Former banking executive and listed-company CFO, experienced in financial management, audit and enterprise risk.

Audiologist and long-serving Cochlear commercial leader, responsible for North American strategy and operations.

Medical-device engineer and former chief executive of Fisher & Paykel Healthcare.

Medical-device and pharmaceutical executive with international commercialization and leadership experience at Johnson & Johnson.

Former media and digital-business chief executive, experienced in strategy, transformation and corporate governance.

Leads corporate legal and governance functions, with extensive in-house legal experience across regulated industries.

Appointed in 2026; experienced in organizational transformation, culture and capability development.

Former BCG healthcare consulting leader and research scientist; appointed CFO in January 2025.

Former services president and CFO, experienced in customer-focused technology businesses.

Joe Schorge founded and leads Isomer Capital as Managing Partner. He identified the opportunity to build diversified access to European technology venture capital in the early 2010s. His responsibilities include investing, portfolio management and development of the firm and team. Earlier experience spans technology operations and investing in the United States and Europe. The manager’s UK legal filings also identify him as R Joseph Schorge.

Isomer Capital is a London-based European technology investment platform combining primary commitments to venture-capital funds, direct company co-investments and secondary purchases of fund interests and company stakes. Its regulated UK manager is Isomer Capital LLP, Companies House OC397905, incorporated February 4, 2015; the manager’s own website states FCA authorisation and regulation. Joe Schorge leads the firm, which Chris Wade co-founded. Published current team members cover fund selection, direct investments, secondaries, finance and investor relations, with offices in London, Amsterdam, Milan, Tokyo and Zurich. Its technology exposure includes AI, deep technology, life-science laboratory automation and climate innovation. Automata’s primary 2022 Series B and 2023 growth-financing announcements identify Isomer as a returning investor. The firm’s thousands of underlying portfolio companies represent indirect exposure through funds as well as direct holdings, and are not all individual Isomer company investments. Isomer Capital Team LLP OC457123 is a separate 2025 legal entity; individual Luxembourg fund vehicles are separately identified. Flagship and secondaries launch targets, institutional cornerstone commitments and headline assets under management are not represented as completed cash fundraising.

Capital F is a United States venture firm investing at pre-seed and seed in health, AI, digital commerce and the digital workplace serving the female economy. Its founders bring experience building and operating businesses and support portfolio companies with commercial strategy, hiring, customer introductions and fundraising. Investments include maternal healthcare, AI trust and safety, sleep care and commerce technology. The firm backs founders of any gender who build products addressing markets shaped by women’s needs and purchasing decisions.

224 Ventures is an early-stage venture firm investing in AI-native startups across applications, robotics, infrastructure and core intelligence. It contributes technical evaluation and commercial support through frontier AI researchers and an operator network spanning research labs, technology companies and enterprise buyers. The firm publishes initial investments of USD1–5 million alongside lead investors and helps founders connect with potential customers, design partners, employees and follow-on investors.

Dawn Dobras is a co-founder and general partner of Capital F and an operator with more than three decades of experience scaling brands. She previously led Credo Beauty and is an entrepreneur-in-residence at Harvard Business School, where she earned her MBA. She supports founders building in health, AI and digital commerce.

Margaret Coblentz is a co-founder and general partner of Capital F. She grew a major retailer’s ecommerce division and founded and bootstrapped luxury direct-to-consumer brand Frances Austen through an acquisition. She is a Stanford Graduate School of Business and UCLA alumna and a founding member of The Council Angels.

Lighthouse Ventures is a Prague-based venture capital firm investing in early-stage technology businesses across Central and Eastern Europe. It backs B2B software, fintech and AI companies with international growth ambitions, typically investing €200,000 to €1 million at the idea and seed stages. Its partners support founders with business development, startup mentoring, acquisitions, marketing and operational advice, drawing on relationships with startup hubs, universities and technology companies. The manager operates Lighthouse Ventures Fund II and an earlier seed fund supported by the Czech ESIF Fund of Funds.

22 Hor Invest is a Brno-based family investment company founded by Radek Horváth and Pavla Horváthová after building and exiting biotechnology business GeneProof. It finances and helps commercialize scientific and deep technology projects in medical technology, AI for healthcare, diagnostics, drug development, biotechnology, nanotechnology, renewable energy and the circular economy. The founders help teams define products and markets, build company structures, implement quality systems and certifications, and assess development projects. Its investments include healthcare AI company Datlowe and drug-discovery company QurieGen. It also supports neuroscience education and research into neurodegenerative diseases through separate philanthropic partnerships.

Technology entrepreneur and investor; founded cloud provider VSHosting.

Digital marketing entrepreneur and startup mentor; co-founded Feedyou.

Startup investor and mentor; founded the Prague Startup Centre.

Performance marketing entrepreneur; founded XLMedia and Team Odeon.

Biotechnology business builder with company management and commercialization experience.

Scientist and biotechnology entrepreneur; founded GeneProof in Brno.

Technology acquisition specialist; previously led corporate development at AVG.

Previously investment associate and investment manager at Lighthouse Ventures.

IT entrepreneur and investor; founded systems integrator Pontech.

Suryansh Chandra co-founded Automata with Mostafa ElSayed after working in computational design at Zaha Hadid Architects. Automata’s own CEO biography says he launched The Mind Distillery in2020 and remained an Automata director until2021. His historical founding affiliation is preserved; he is absent the current operating roster and no exact employment end date is guessed.

Current-status correction reviewed7October2026: Murali Venkatesan announced in his own public post that the preceding week was his final week at Danaher after seven and a half years. His Danaher Ventures leadership is therefore former, although the corporate page still labels him regional head and the January2026 Automata release used Global Head. Exact employment-end day and successor are undisclosed. This employment departure does not establish resignation from his separately recorded Automata statutory board appointment. His official Danaher biography describes electrical/computer engineering doctoral training at Illinois, earlier Lam Research and Illumina work, Stanford Executive Program and University of Western Australia degrees; the URL alone does not substantiate an MD degree. Previous sourced biography, subject to the current-status correction above: Murali Venkatesan is a Danaher Ventures executive leading healthcare and biotechnology investment and partnership work. Danaher’s current own biography calls him Vice President and Head of Danaher Ventures, Americas and Europe, with earlier technology roles at Illumina and Lam Research and an electrical and computer engineering PhD. Automata’s January2026 financing announcement confirms his board appointment; CompaniesHouse records the actual legal director appointment November6,2025 under Bala Murali K Venkatesan. No personal check is inferred.

Nan Li is a Dimension co-founder and managing partner working at the intersection of computing and life science. Biocom’s own professional biography specifically names Automata among his investments. CompaniesHouse confirms his Automata director appointment July31,2023. Distinct from unrelated academics and economists with the same name; no personal cash check inferred. Dimension’s current Investment directory and March2026 legal filing confirm Nan Li as co-founder/managing partner. His existing authentic portrait and separate current Automata statutory directorship are preserved.

Kamran Adle is an Automata director appointed January15,2024 according to CompaniesHouse. Octopus Ventures’ own profile identifies him as a health-investment partner with entrepreneurship and earlier JPMorgan experience. Institutional board representation does not establish a personal cash investment.

John D. Young is a former Pfizer executive who retired in 2022 and now advises Automata. Contributes pharmaceutical leadership, commercial strategy and scientific-development experience. His advisory role is distinct from a statutory director or personal investment.

Rui Campos is vice president of product at Automata. Product executive with experience developing and scaling products in automation and regulated industries.

Patrick Jamieson is senior vice president of operations at Automata. Operations executive with experience at Alloy Therapeutics, Ginkgo Bioworks and other technology and life-sciences businesses.

Michael Asham is global head of sales (current heading; biography says presales) at Automata. Molecular biologist and laboratory robotics specialist with experience in genomics, diagnostics and liquid handling. Own current heading says Global Head of Sales; the body retains an older Presales title.

Joe Stringer is executive chairman and president of corporate development at Automata. Healthcare executive and former Octopus investor responsible for corporate development and strategic relationships. His earlier investment activity was on behalf of institutions, not an inferred personal cash check.

Henni Roini is chief of staff at Automata. Oversees strategic projects, board reporting and company operations. Previously worked in venture investing at Balderton Capital and commercial roles at HubSpot.

Jennifer Howson is chief financial officer at Automata. Chartered accountant and finance executive with previous roles at Diageo, L’Oreal and PwC and experience building growing consumer businesses.

Mostafa ElSayed is ceo and co-founder at Automata. Architect and computational-design researcher who co-founded Automata with Suryansh Chandra after working at Zaha Hadid Architects. Leads its transition from affordable robotic arms to laboratory automation.

Arianna Taboada directs learning and impact at Hopelab, overseeing equitable evaluation and organizational learning across investing, grants, research and field building. She trained in public-health social work at the University of North Carolina at Chapel Hill and previously worked on community-health research in Mexico and the United States.

Arielle Geismar is a Hopelab board member and a technology-policy organizer and strategist. Her work includes responsible technology, youth mental health, gender and LGBTQ+ advocacy. She formerly co-chaired Design It For Us and served as student body president at George Washington University.

Brian Rodriguez leads people and culture at Hopelab. His role focuses on the organization’s workplace culture, employee experience and alignment with its mission and values.

Courtney Chang is Hopelab’s head of strategy, aligning programs, partnerships and resources with its organizational priorities. She previously spent four years as Hopelab chief of staff and worked on health initiatives at IDEO.org and HIV/AIDS policy at PEPFAR. Her degrees include international health at Georgetown and an MBA/MPH at Johns Hopkins.

David Bayne directs policy at Hopelab, developing policy positions and engaging young people in policymaking. He previously led the Thurston County health department and held public-affairs and government-relations roles in Washington and Georgia public-health agencies. He earned an MPH at Emory University. He is distinct from IP Group executive David Baynes.

Elisa Sims is Hopelab’s accounting manager. She oversees accounting operations and brings experience across multiple industries to the organization’s financial management.

Emma Bruehlman-Senecal is a principal researcher at Hopelab. She leads youth-engaged social and behavioral research and translates findings into design, research and policy recommendations. Earlier work included Hopelab’s Nod and imi products and postdoctoral research at UC Berkeley on mobile depression-treatment tools.

Emma Leiken directs youth power at Hopelab, focusing on technology policy and youth well-being. She previously led TikTok’s global youth-safety policy team and a youth-focused technology portfolio at Omidyar Network, where she co-founded the Responsible Technology Youth Power Fund.

Erin Sietstra heads investments at Hopelab, sourcing and managing companies addressing teen and young-adult mental health. She previously led transactions and business analytics at Johnson & Johnson Innovation and worked in healthcare strategy at Leerink Partners. She holds a Stanford MBA and a Harvard biology degree.

Jana Haritatos is Hopelab’s chief science and innovation officer. She guides scientific priorities and partnerships and translates behavioral-science insights into youth-centered initiatives. She co-founded Purpose Commons with Tony Burrow.

Jaspal Sandhu is Hopelab’s president and CEO. He leads its youth mental-health research, investments and funding programs, having previously served as executive vice president. His background combines design innovation, social entrepreneurship and health equity, including co-founding and leading Gobee.

Joshua Lavra is a principal at Hopelab working across design, technology and youth mental health. Trained in chemical engineering, Lavra combines analytical methods with human-centered creative problem solving. The published principal role is not described as an investing position.

Juan Martinez is Hopelab’s vice president of strategic communications and policy. He leads communications and public-policy work focused on youth mental health. Earlier roles include communications leadership at the Legal Defense Fund, press secretary to Massachusetts Governor Deval Patrick and senior program officer at the Gates Foundation.

Julie Tinker is a Hopelab principal focused on design, social impact and health equity. She develops programs centered on Black and Brown young people. Her training includes communication and sociology at Stanford and an MFA in design at the School of Visual Arts; the principal title is not an asserted investment role.

Kim Bright is Hopelab’s vice president of finance and operations. She oversees organizational infrastructure and operational capabilities. Earlier finance, people and operations roles include the Campaign Legal Center, Brookings Metropolitan Policy Program and National Policing Institute, alongside technology-contract work at Booz Allen Hamilton.

Melina Taylor directs information technology at Hopelab Foundation in San Francisco. Her experience covers cybersecurity, infrastructure, systems administration and IT strategy across education, biotech and other industries. She studied psychology at Yale.

Mike Parent is a principal researcher at Hopelab, leading research partnerships and projects in youth mental health. He holds a doctorate in counseling psychology and an MBA and brings approximately fifteen years of research experience.

Monique Jaquez manages employee experience and office operations at Hopelab. Her earlier work included patient care and advocacy, and she has volunteered with community and grassroots organizations.

Nathaan Demers is a principal investor at Hopelab and a psychologist with clinical and leadership experience. His work connects behavioral health, technology and care systems. He earned his doctorate at the University of Denver and has worked in counseling, inpatient care and integrated primary care.

Pam Omidyar founded Hopelab, initially exploring whether a video game could improve treatment adherence among young people with cancer. That work led to the scientifically evaluated Re-Mission game. She remains a guiding figure at Hopelab and co-founded The Omidyar Group with Pierre Omidyar.

Phuong Pham is publicly listed as Hopelab’s director of communications and narrative change. Her experience combines digital media, storytelling and philanthropy, including earlier work at SoCal Grantmakers, Mission Investors Exchange and the Vilcek Foundation. The page biography retains an earlier marketing and digital-strategy title; the current directory title is used for her Hopelab role.

Robin Hayashi is Hopelab’s creative lead, working in graphic design, design research and strategy. Earlier experience includes IDEO.org, IDEO and MIT. She holds a graphic-design BFA from the Rhode Island School of Design.

Robin Raskob is Hopelab’s senior manager for media and editorial. She oversees editorial work and media relations, creating content that represents young people’s experiences and supports mental-health equity.

Sabrina Fisher directs finance at Hopelab. Her earlier nonprofit financial-leadership roles include the Campaign Legal Center, Brookings Economic Studies Program and the Society for Neuroscience. She holds a public-policy master’s degree from American University.

Samira Pingali is a principal leading translational science at Hopelab. She connects behavioral-science research with practical opportunities in adolescent development and well-being, including support for underrepresented researchers. She holds an MPH from Columbia University and has worked across mental-health research, operations and policy.

Stefano Bertozzi chairs Hopelab’s board. His background includes health-policy scholarship at UC Berkeley, leading HIV and tuberculosis programs at the Gates Foundation, evaluation research at Mexico’s National Institute of Public Health and leadership of the WHO Global Programme on AIDS. Older institutional titles in the Hopelab biography are background affiliations rather than newly verified current outside appointments.

Tracey Kirui is Hopelab’s chief of staff and strategic partnerships, coordinating priorities with the CEO and building mission-related partnerships. Earlier work spans federal health policy, Medicaid and behavioral-health strategy and inclusive-leadership consulting. She also serves on the Lifelong Medical Care board.

Wizdom Powell is a Hopelab board member and the inaugural CEO of Unified Youth. Her work spans mental and behavioral health, education, public policy and community interventions. She earned psychology and public-health graduate degrees at the University of Michigan and has held tenured academic appointments.

Hopelab Foundation Inc. is a San Francisco nonprofit social-innovation institution and impact investor working at the intersection of technology, behavioral science and youth mental health. Founded by Pam Omidyar, it conducts youth-engaged research, funds community-centered initiatives and invests in companies improving the well-being of adolescents and young adults, with particular attention to Black, Brown, Queer and underserved communities. Its early Re-Mission video-game research addressed treatment adherence among young people with cancer. The current Ventures program combines financial investment with research, design and strategic support; its own site reports 28 active companies and USD20M deployed, which is cumulative deployment rather than an LP fund closing or an individual company allocation. Its current published portfolio includes pediatric mental-health provider Healthy Young Minds, Blackbird Health, AI crisis-response training company ReflexAI and several digital behavioral-health companies. Jaspal Sandhu is the current president and CEO; Margaret Laws, CEO from 2015 to 2025, is now executive in residence. The public directory names 32 staff, founder and board members, all included in this profile. Its grantmaking and institutional operating finances are distinct from venture fund raises, and no external-LP fund close has been established. Hopelab is associated with The Omidyar Group; that network association does not establish a separate parent investment ticket.

Aliza Lopez supports communications and policy at Hopelab. Her work covers youth participation, peer support and equitable access to mental-health resources. She previously worked on Headstream youth and accelerator programs and studied health, behavior and society at the University of Rochester.

Alyssa Gabbidon is a research assistant at Hopelab working on youth-centered mental-health research, particularly for Black, Brown and Queer young people. She studied psychology and political science at Duke University and has experience in psychophysiology and policy research.

Amy Green is a clinical psychologist and Hopelab’s head of research. She studies youth mental-health equity and implementation of evidence into policy and services. Her previous positions include UC San Diego academic appointments and vice president of research at The Trevor Project.

Amy Hauck Newman, Ph.D., is NIDA scientific director and a senior investigator in the Molecular Targets and Medications Discovery Branch, Medicinal Chemistry Section. Her official NIH scientist biography describes designing and synthesizing ligands to study central nervous system G-protein coupled receptors and monoamine transporters, and developing tools for neuropharmacological research.

Lorenzo Leggio, M.D., Ph.D., is NIDA clinical director and a senior investigator in the Translational Addiction Medicine Branch. He founded the Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, a joint NIDA/NIAAA laboratory. His official NIH scientist biography describes translational addiction research, experimental medicine studies, clinical trials, biospecimen analysis and large-scale data analysis.

Daphne Zohar is the founder and former CEO and board director of PureTech Health, and the published founder, CEO and board member of Seaport Therapeutics. She co-founded PureTech’s Karuna Therapeutics and helped build its company-creation and research model. On April9,2024 she left PureTech’s CEO and director roles to lead Seaport, remaining a senior advisor and board observer under a dated agreement. PureTech’s2025 annual report confirms that she resigned the observer role August9,2025 and served as senior advisor through April8,2026. These historical PureTech appointments are not asserted to remain current. Her original Seaport portrait is authenticated by the named current leadership card; the site’s separate image filenames are not used to infer identity. No personal investment is inferred from founding or corporate ownership.

OculAudio Corti AS is a Norwegian hearing-technology development company working on a smart eyeglass accessory for cochlear implant users. In March 2023 it announced a research and development collaboration with Cochlear Limited to evaluate compatibility between OculAudio’s multiple-microphone beamforming technology and Cochlear’s sound processors, aiming to improve listening in noisy environments. The development program was jointly financed and Cochlear made its first investment in the company. Incorporated in January 2023, OculAudio Corti AS is a separate legal company from OculAudio AS, which develops the broader OculAudio hearing-assistance platform.

Qbee provides a software platform for operating fleets of embedded Linux devices and intelligent edge infrastructure. Engineering teams use its device agent and control plane to automate configurations, deploy operating-system and application updates, run containers and scripts, monitor device health, and remotely troubleshoot systems through encrypted connections. Its security tools track vulnerabilities and configuration changes. The platform supports mixed hardware and Linux distributions, including Debian, Ubuntu and Yocto, and integrates with existing update frameworks such as RAUC and SWUpdate, helping industrial and IoT product companies manage deployed devices throughout their lifecycle.

Davide Scaglia is listed by Friulia as Statutory Auditor. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Published as Steffan Thorvaldsen; the official current Norwegian company register gives the full name Steffan Roxrud Thorvaldsen.

Alberto Cappel is listed by Friulia as Chair, Board of Statutory Auditors. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Antonella Lonciari is listed by Friulia as Statutory Auditor. The issuer’s current governance page records the relevant shareholder-assembly appointment on2025-06-17. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Barbara Bortolussi is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Lucia Arena is listed in Friulia’s current public staff directory as Ufficio del Personale. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Luisa De Marco is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Paolo Santin is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; a genuine public portrait and wider career biography were not verified.

Renzo Chervatin is listed by Friulia as Board Director. The issuer’s current governance page records the relevant shareholder-assembly appointment on2024-07-22. This governance/audit affiliation is distinct from an executive or investment-team job; his genuine portrait and career biography are corroborated below by the published self-authored CV. His self-authored CV published by Fondazione Università Ca’ Foscari describes banking work from1985, roles at UniCredit from1998, and territorial-development responsibility for the northeast from2017. It lists regional ABI and other advisory affiliations. These are qualified CV career statements, distinct from his current Friulia board appointment; no separate employer role or personal investment is inferred.

Andrea Foschia is listed in Friulia’s current public staff directory as Amministrazione e Servizi Generali. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Massimiliano Viola is listed in Friulia’s current public staff directory as Sistemi Informativi. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Sara Spogliarich is listed in Friulia’s current public staff directory as Segreteria Generale e Comunicazione. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Bertoz is listed in Friulia’s current public staff directory as Tesoreria & Debt Advisory. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandro Mazzi is listed in Friulia’s current public staff directory as Internal Audit e Compliance. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Elisa Tiberio is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Gabrijel Zetko is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Samuele Burlo is listed in Friulia’s current public staff directory as Investment Analyst. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Stefano Zonch is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Digital-health venture developing a personalised toolkit for women navigating menopause, midlife and later life. Its published model combines proprietary algorithms with objective measurements and user-reported information to help women understand changes in their bodies, track their wellbeing and manage personal health. The company describes an aim to improve women’s experience of menopause and close gaps in data on female health and ageing. Khyria originated with The Sanguine Lab and is listed in Velocity Partners’ portfolio. Its product website currently does not resolve, so present operating status, product availability and clinical effectiveness remain unconfirmed.

London-based Imperial College spin-out developing wearable sensing and AI software to quantify Parkinson’s motor symptoms and support more personalised care. Its proprietary mechanomyography and inertial sensors measure muscle activity and movement, while algorithms estimate tremor, bradykinesia and rigidity. Its current StimSense system helps clinicians assess symptoms during deep brain stimulation programming and is intended to shorten and automate adjustment sessions. The wider platform supports symptom assessment, medication-response tracking, home monitoring and therapy evaluation. SERG reports a pilot study with Boston Scientific; these company-reported findings do not establish general regulatory clearance or treatment efficacy.

Riccardo Dentesano is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandro Villatora is listed in Friulia’s current public staff directory as Senior Investment Officer. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Fioravanti is listed in Friulia’s current public staff directory as Senior Investment Officer - specialista mercato. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Sarah Barbarossa is listed in Friulia’s current public staff directory as Investment Manager. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Alessandra Ramani is listed in Friulia’s current public staff directory as Vice Direttore Servizi Corporate. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Roberta Terpin is listed in Friulia’s current public staff directory as Vice Direttore Investimenti. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Andrea Cauzer is listed in Friulia’s current public staff directory as Direttore Servizi Corporate. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Claudia Filozof is published by aMoon as External Adviser. Physician and drug-development specialist whose biography describes Fortrea leadership in metabolic and liver diseases. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Federica Seganti is listed in Friulia’s current public staff directory as Presidente e Amministratore Delegato. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Isaac Devash is published by aMoon as Venture Partner. Helped establish Growth, Velocity and the8400HealthNetwork; brings international investment and business-development experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Marco Signori is listed in Friulia’s current public staff directory as Direttore Generale. Friulia is the regional development finance and investment company headquartered in Trieste, supporting companies developing operations in Friuli Venezia Giulia. No specific personal investment check or undocumented prior career is inferred from this affiliation.

Samuel Moed is published by aMoon as Venture Partner. Former Bristol Myers Squibb corporate-strategy executive with global biopharmaceutical transaction and integration experience. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred.

Friulia is the regional development finance and investment company of Friuli Venezia Giulia, Italy, founded in1967 and headquartered in Trieste. Its legal name is Finanziaria Regionale Friuli Venezia Giulia – Società per Azioni – FRIULIA S.p.A., tax/VAT identifier00051580322. The autonomous region holds86.733% according to the current shareholder disclosure. Friulia takes minority equity stakes and provides financial and strategic support for companies developing operations in the region, including businesses headquartered elsewhere. It also coordinates strategic regional holdings. Its portfolio includes biotechnology, information technology and AI-related industrial businesses; a2021 subscription supported Neurala’s European subsidiary as part of the parent’s broader financing. Friulia itself is recorded as a regional investment company and institutional investor; its separate SGR/fund-manager subsidiaries are not merged. Corporate share capital, portfolio asset values and public programme budgets are not represented as venture-fund closes.

Michael Sherman is published by aMoon as External Adviser. Physician and healthcare consultant at Sherman Healthcare Solutions; own biography describes additional advisory work with RA Capital. This is an advisory or venture-partner affiliation; no employment or personal investment is inferred. Current source-verified RA affiliation: Michael Sherman holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: MD , MBA , MS , BA. Universities identified in the own biography: University of Pennsylvania, Harvard University, Yale University. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Scott Stanford co-founded ACME in 2018 and is a Partner. He previously co-founded Sherpa Capital and Silicon Foundry. His background includes co-leading Goldman Sachs’s global internet investment banking practice in San Francisco and working at early-stage LookSmart before its public listing. He advises founders on enterprise adoption and commercial relationships. He studied Social Studies at Harvard College and earned an MBA at Harvard Business School. SEC filings distinguish his manager authority from any separate personal investment.

Bar Katzir is published by aMoon as Receptionist. Supports reception and operations following military service; no separate investment responsibility is inferred.

Karin Zaum is published by aMoon as Executive Assistant. Previously supported Bionic Stork executives and worked at Amdocs; holds an MBA from Heriot-Watt University.

Mike Derrick, identified in ACME’s SEC filing as Michael James Derrick, is the firm’s Chief Financial Officer and Chief Compliance Officer. He previously held finance leadership positions at Sherpa Capital and Trident Capital and worked across private equity and venture finance at Thomas Weisel Partners, Trust Company of the West and Apax Partners. Earlier experience includes fund administration at Mourant and HSBC and accounting training at Ernst & Young in Jersey. Career fund totals describe prior organizations, not new ACME fundraising.

Rebecca Peretz is published by aMoon as Executive Assistant. Supports Growth and Edge investment teams; previously coordinated development and donor activities at Hadassah Hospital.

Madiha Danish is ACME’s Assistant Controller. She contributes financial accounting, analysis and management expertise. Previously she was a senior consultant at Armanino LLP. She earned a bachelor’s degree in business management and international business at Northwood University; the current published biography describes ongoing CPA studies rather than an already earned credential.

Masha Sherman is published by aMoon as Operations Manager & Executive Assistant. Manages Boston office operations and supports Tomer Berkovitz; previously led operations at Valiantys.

Natalie Chazon is published by aMoon as Executive Assistant. Provides executive support to Yair Schindel and the finance/legal teams; has business and behavioral-sciences education.

Maayan Janus is published by aMoon as Marketing Communications Manager. Health communications professional with biology and business education, responsible for marketing content and communications.

Jenny Redling is ACME’s Chief of Staff, supporting leadership priorities, cross-team coordination and relationships with investors and founders. Her professional experience spans venture capital, corporate innovation and nonprofit organizations, including earlier work in fundraising for education and community initiatives. She studied politics and psychology at the University of San Francisco.

Keren Ditkovsky is published by aMoon as Bookkeeper. Experienced bookkeeping professional previously at Bright Machines; studied bookkeeping at Ruppin College.

Sarit Tannenbaum is published by aMoon as Assistant Controller. Accountant with prior EY technology and biotechnology assurance experience.

Hany Nada co-founded ACME in 2018 and is a Partner. He advises company leaders on global expansion, commercial strategy and transactions. He previously co-founded GGV Capital, served as a managing partner through October 2016 and remained a venture partner until 2018. Before GGV he worked in equity research at Piper Jaffray. His current ACME biography identifies board roles at AviaGames, Canopy, Forma.ai and Forte. He earned degrees in economics and political science at the University of Minnesota.

Nataly Lipovyak is published by aMoon as Senior Bookkeeper. Former Onyx Industries bookkeeping-team leader; holds graduate training in economics engineering.

Christian Tang-Jespersen is a Partner at ACME who advises growth-stage technology businesses. His operating experience includes international chief executive roles and leading Heptagon through growth and acquisition. He works with founders on scaling organizations, international expansion, transactions and exit planning. The manager describes a career spanning the United States, China, Singapore, Switzerland and Denmark; historical outside positions are not treated as current appointments without further evidence.

David Dubinsky is published by aMoon as Controller. Former Reznik Paz Nevo accountant whose background includes auditing business and investment financial statements.

Yodfat Melzer is published by aMoon as VP Finance. Manages tax, valuation, portfolio monitoring and transaction-structuring support.

Alex Fayette is a Partner at ACME focused on technically complex startups in aerospace and defense, next-generation computing, technology-enabled biology, physical AI, energy and materials. He helps founders connect engineering progress with commercialization and company building. His current manager biography identifies board involvement with Akash, Avia Games, Laurel, Replika, Sphere Semi, True Anomaly and Muon Space. Previously he worked in investment banking at J.P. Morgan and studied economics at Yale.

Gaby Hirsch is published by aMoon as VP Investor Relations. Leads investor relationships, marketing, communications and brand activities.

Noah Lasson is published by aMoon as Chief Compliance Officer & CISO. Oversees compliance and information-security programs for the healthcare investment platform.

BeyondOS is an AI research and entertainment software company building tools to create, operate, and monetize interactive content. Its workflows turn prompts and reference inputs into game sprites, animations, playable logic, scenes, and mechanics. It also develops agents for game design, level and economy balancing, live operations, and monetization, coordinated through a game studio workflow. Its consumer platform Makermint applies these tools to creating and publishing interactive experiences. BeyondOS previously developed design and decor experiences including Decor Society; its current platform focuses on broader AI-assisted interactive content creation.

Anthony Hill founded Adapdix, the predecessor to Aispire. He was its founder and CEO in its December 2020 issuer financing release; this historical CEO title is not asserted as his current role.

Co-founder of BeyondOS, explicitly identified in the founder’s primary financing announcement. The company’s current own team directory also lists Anton Gauffin.

Co-founder of BeyondOS, explicitly identified in the founder’s primary financing announcement. The company’s current own team directory also lists Ben Dickenson.

Cory Baldwin previously founded and led sensemetrics, acquired by Bentley Systems in 2021.

Marc Sperschneider founded and leads X2 Equity and formerly was managing shareholder of MatriX Technologies.

Paul McCafferty has co-founded two venture-backed companies and led engineering for large-scale data systems.

Renee Sass previously held senior finance and strategy roles at NRG Energy and was a partner at Fairlead Advisors.

Skip Glass previously led URoam, served as COO of Kiva, and held a product role at Sybase.

Aleda Johnson leads brand and development at ACME, working across communications, strategic partnerships and operating initiatives for the firm and its portfolio. Before ACME she spent five years in program and operations work at Atomic Venture Studio. She holds a bachelor’s degree in Liberal Studies from the University of Wisconsin, Whitewater.

Osnat Tirosh is published by aMoon as Chief People Officer & Chief of Staff. Human-capital executive with experience advising technology-company leadership and managing organizational growth.

Noam Waldoks is published by aMoon as Chief Legal Officer. Lawyer who helped form Growth as outside counsel in2018 and joined the platform in2020.

Aike Ho is a Partner at ACME focused on frontier health, where robotics, synthetic biology and engineering meet. She supports technologies that address difficult healthcare constraints and also considers selected consumer businesses. Her current manager biography identifies board work with Conceivable Life Sciences, Arya Health, Camber and Brightside. She graduated from Yale University. Her approach combines business guidance and support for founders building complex companies.

Irena Katsman is published by aMoon as Chief Financial Officer. Finance leader responsible for reporting, treasury and corporate finance, with experience at public and multinational businesses.

Shachar Elias is published by aMoon as Intern. Previously performed family-office real-estate and financial analysis; supports Growth market and investment research.

Daniel Sass is published by aMoon as Associate. Physician trained at the University of the Witwatersrand, with emergency-medicine practice experience in Cape Town.

David Esra is published by aMoon as Analyst. Physician trained at the University of the Witwatersrand; supports early-stage Velocity investments and the Alpha value-creation team.

Jeff Ekberg, legal name Jeffery David Ekberg, is brokerageFINOP in currentFINRA filings and ChiefFinancialOfficer of the separateBrooklandsadvisoryLP in2026FormADV. Brooklands’ own archived directory named him SeniorAdvisor followingTPG/Newbridge/Colony/KPMGroles. He is a CPA and studiedbusiness/accounting atCaliforniaStateUniversityLongBeach.

Jill DeMayo, legal name Jill Ellen DeMayo, is ChiefComplianceOfficer of BrooklandsCapitalStrategiesBDLP in current2026 FINRA filings. The archived own directory also identified her as an IQ-EQ director with priorGreyline/VistaCompliance/FINRAexperience. Her brokeragecompliancerole isdistinctfromMollyUnderwood’sadvisoryLPcompliancerole.

Molly Underwood, legal name Molly Sager Underwood, is Chief Compliance Officer of BrooklandsCapitalStrategiesLP in its2026 FormADV. The archived own directory listed her as ChiefAdministrativeOfficer after CFO/COO roles at alternative managers and11 years at TPG. She is a CPA with accountingdegrees fromTexasA&M; currentunit-specificcompliancetitle isdistinguishedfromolderadministrativetitle.

Rey Mozer is published by aMoon as Associate. Physician with clinical and healthcare-strategy experience who evaluates later-stage medical and healthcare technologies.

Sharon Feldman is published by aMoon as Analyst. Life-sciences community builder who founded the Jerusalem chapter of Nucleate Israel before joining the investment team.

Trey Parra was an Associate in Brooklands’ archived own directory focused on advisory and campaign execution after analyst roles at DirectAccessCapital and PlainsCapitalBank. He holds finance degrees from USC and OklahomaState. Current own firm LinkedIn corroborates affiliation; a newer seniority/title is not inferred from secondary databases.

Adam Kotzen is published by aMoon as Principal. Former Credit Suisse investment banker specializing in corporate transactions; evaluates later-stage Growth investments.

Hagai Marmor-Kollet is published by aMoon as Associate. Life-sciences researcher with molecular diagnostics and therapeutics experience, including a platform leadership role at1E Therapeutics.

Max Del Vento, legal name Maximiliano Del Vento, was Managing Director in Brooklands’ archived own directory, focused on US/LatinAmerican distribution and investor engagement after Centerbridge and PartnersGroup roles. FINRA CRD5348264 confirms Brooklands registration May2018 throughSeptember2025 and currently not registered. No present Brooklands employment is asserted.

Maxwell Williamson, called Max Williamson in Brooklands’ archived own directory, was its Vice President focused on advisory and campaign execution. He previously worked at HiveAI and BankofAmericaMerrillLynch and studied economics/sustainability at Stanford. Current own firm LinkedIn identifies his affiliation but does not independently verify an updated title.

Jinny Choi’s Brooklands own archived directory identifies her as Managing Partner and Co-Founder of Pacific Bridge Asset Management, an affiliate of Brooklands, after joining Brooklands in2016. Earlier work included Bridgewater, UBS, GE and Morgan Stanley. This is explicitly an affiliated/historical directory attribution rather than an invented current Brooklands employee title.

Patrick Rivers is published by aMoon as Portfolio Manager. Joined in2024 after biotechnology investment research at Aquilo Capital Management; works on public healthcare equities and private therapeutics.

Dan Carroll, legal name Daniel Ashton Carroll, co-founded Brooklands Capital Strategies after helping establish TPG’s Asian investment business. Its archived own bio lists Harvard economics and Stanford MBA education. Current2026 FINRA confirms Managing Partner at the brokerage, and the advisory affiliate reports him as Limited Partner. His personalboard/investingactivities are not automatically Brooklandsfundchecks.

Kirk Syme was identified as Partner in Brooklands’ own archived directory, focusing on project management and advisory services across asset classes. He previously worked at Weston Presidio and Morgan Stanley and studied at Georgetown and Berkeley Haas. A complete current operating roster is not published; this role is source-qualified as last confirmed.

Robert Shirley is named in the official NIH OCIO leadership directory as Director, Office of IT Architecture. The office supports NIH’s information technology, governance, data security and research infrastructure.

Roy Wiesner is published by aMoon as Partner. Leads Velocity investments and the Roche Diagnostics StarFinder collaboration; own biography identifies IBEX Medical Analytics and Eleos Health board service.

Brooklands Capital Strategies is a San Francisco capital-raising and strategic-advisory platform founded by Peter McMillan and Dan Carroll in2014. Its activities span alternative-manager fund formation, investor relations, direct-investment syndication, co-investments and secondary offerings. The current website identifies Brooklands Capital Strategies BD, LP, a FINRA-member broker-dealer (CRD281951); the2026 FINRA filing identifies Brooklands Capital Strategies LP (CRD341650) as a separately regulated investment-advisory affiliate under common control. The brokerage is owned by Brooklands Capital Strategies Management, LP and has Brooklands Capital Strategies (GP), LLC as general partner. These legal capacities are qualified within the broader brand rather than treating every client fundraising mandate as a Brooklands portfolio investment. Akili’s May9,2018 issuer announcement explicitly names Brooklands Capital Strategies among participating investors in its USD55M SeriesC; the exact underlying subscribing Brooklands vehicle and its individual check are not published there. A ten-person archived own directory is retained with historical/current/affiliate roles qualified against2026 regulatory filings. The advisory affiliate reports one private fund, BCS Viestra LP; its USD50M regulatory gross asset value is not an actual fund-close amount. Client capital raised, prior TPG fundraising experience and advisory mandates are not recorded as Brooklands fund corpus or company cash.

Craig Hayn is named in the official NIH OCIO leadership directory as Acting Chief Information Security Officer. The office supports NIH’s information technology, governance, data security and research infrastructure.

Jason Hitchcock is named in the official NIH OCIO leadership directory as Director, Information Technology Policy Review Office. The office supports NIH’s information technology, governance, data security and research infrastructure.

Moshic Mor is published by aMoon as General Partner. Entrepreneur and former SPL WorldGroup chief executive who co-leads the early-stage Velocity strategy.

Peter McMillan co-founded Brooklands Capital Strategies following14 years at TPG, including capital formation across geographies and asset classes. Brooklands’ archived own directory identifies him as Managing Partner;2026 FINRA identifies him as brokerage CEO/Managing Partner and the advisory affiliate reports him as Limited Partner. His prior client/TPGfundraising experience is not Brooklands-ownedfundcapital.

Yaron Daniely is published by aMoon as General Partner & Head of aMoon Alpha. Scientist and healthcare executive who co-leads Velocity and heads the Alpha operating-support team.

Joe Henke is named in the official NIH OCIO leadership directory as Acting Deputy Chief Information Officer; Acting Deputy Director, OCIO. The office supports NIH’s information technology, governance, data security and research infrastructure.

Yair Schindel is published by aMoon as Co-Founder & Managing Partner. Physician and healthcare entrepreneur who co-founded the platform with Marius Nacht; his own biography dates the founding to2017.

David M. Murray, Ph.D., is NIH associate director for prevention and director of its Office of Disease Prevention. The official ODP biography supplies the distinguishing middle initial M. This verified institutional identity is kept separate from an unrelated pre-existing blank David Murray record.

Jonathan Green is listed as director of the NIH Clinical Center on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Maureen Falvella is named in the official NIH OCIO leadership directory as Chief Information Officer; Director, Office of the Chief Information Officer. The office supports NIH’s information technology, governance, data security and research infrastructure. The appointment took effect on 26 July 2026.

Joni Rutter is listed as director of the National Center for Advancing Translational Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Raymond Jacobson is listed as director of the Center for Scientific Review on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Steven Schiff is listed as director of the John E. Fogarty International Center on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Wendy Weber is listed as director of the National Center for Complementary and Integrative Health on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Amy Adams is listed as acting director of the National Institute of Neurological Disorders and Stroke on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment. Amy Bany Adams is the acting director of NINDS, as confirmed by the current institute leadership directory. An official January2026 workshop biography describes her transition to acting director in that month. Her earlier NINDS service includes founding and leading the Office of Neuroscience Communications and Engagement; she also directed NIDCR science policy and analysis. This enrichment preserves the existing AmyAdams NIH component identity and prior NIH role, rather than creating a second individual. Her genuine NINDS portrait was published in2022, separately from current leadership verification.

Andrea Beckel-Mitchener is listed as acting director of the National Institute of Mental Health on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Courtney Aklin is listed as director of the National Institute of Nursing Research on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Erica Brown is listed as acting director of the National Institute of General Medical Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Kyle Walsh is listed as director of the National Institute of Environmental Health Sciences on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Monica Webb Hooper is listed as acting director of the National Institute on Minority Health and Health Disparities on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Peter Joseph Embí is listed as director of the National Library of Medicine on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Griffin Rodgers is listed as director of the National Institute of Diabetes and Digestive and Kidney Diseases on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Jonathan E. Burke is listed as director of the National Institute of Dental and Craniofacial Research on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Bruce Tromberg is listed as director of the National Institute of Biomedical Imaging and Bioengineering on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Debara Tucci is listed as director of the National Institute on Deafness and Other Communication Disorders on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

George Koob is listed as director of the National Institute on Alcohol Abuse and Alcoholism on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

John Gaitanis is listed as director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

John Powers III is listed as acting director of the National Institute of Allergy and Infectious Diseases on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Judy Cho is listed as director of the National Human Genome Research Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Richard Hodes is listed as director of the National Institute on Aging on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Anthony Letai is listed as director of the National Cancer Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

David Goff is listed as acting director of the National Heart, Lung, and Blood Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

Michael Chiang is listed as director of the National Eye Institute on NIH’s official institute/center director directory, reviewed 23 September 2026. This affiliation is scoped to the named NIH component, separate from the central NIH directorate. The directory does not disclose an individual grant ticket or a company investment.

CICC Capital is the private investment fund management subsidiary of China International Capital Corporation. It manages private equity investments and funds of funds, supporting technology commercialization and industrial development through capital and portfolio services. Its strategies span emerging technologies, healthcare and other growth industries, including a dedicated Shenzhen neuroscience and brain-inspired intelligence fund.

OYMotion develops neural-signal sensors, AI decoding software and robotic devices for rehabilitation, assistive mobility and human-machine interaction. Its products include EMG-controlled bionic prosthetic hands, dexterous robotic hands, EEG equipment and wearable rehabilitation exoskeletons. The Shanghai company combines brain-computer interfaces with robotics and embodied intelligence.

Arfan Ikram is a physician, epidemiologist and professor who became president of ZonMw and a member of NWO’s executive board in August 2022. He also heads the Epidemiology Department at Erasmus Medical Center. His research has addressed dementia, stroke, brain ageing and life-course epidemiology, including the Rotterdam Study.

Ena Voûte joined NWO’s executive board and became chair of its Applied and Engineering Sciences domain on March 16, 2026. She is a professor of industrial design engineering at Delft University of Technology, where she previously served as faculty dean and then pro vice rector for international affairs. Her earlier career included marketing and management roles at Unilever and Philips.

Ferdinand Grozema is professor of Optoelectronic Materials at Delft University of Technology. He became chair of NWO’s Science domain and an executive-board member on September 1, 2026, succeeding Jan de Boer. He studied chemistry in Groningen, earned his doctorate in Delft in 2003 and has researched molecular and materials properties for optical and electronic applications. He joined the domain board in 2023.

Guda van Noort is professor of Persuasion and New Media Technologies at the University of Amsterdam. She became interim chair of NWO’s Social Sciences and Humanities domain and an interim executive-board member on June 1, 2026, succeeding Antal van den Bosch. Her research examines digital media and persuasive communication. She has participated in the domain board since 2023.

Jan de Boer is a professor of theoretical physics at the University of Amsterdam. He joined NWO’s executive board and chaired its Science domain from September 2020, after participating in the earlier FOM and NWO domain governance. Ferdinand Grozema succeeded him effective September 1, 2026. The executive-board directory retains his biography and portrait; it is qualified here as historical rather than current leadership.

The Dutch Research Council, NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek), is a Netherlands public-law research funding organisation operating under the Ministry of Education, Culture and Science. It supports scientific research, national research infrastructure, knowledge transfer and innovative research programmes across natural sciences, engineering, social sciences and health. Its Take-off programme has supported research-derived startups, including a published June 23, 2017 phase-two award to MRIguidance; the specific award amount, contractual instrument and payment are not inferred from general programme limits. NWO is distinct from NWO-I, the separate private-law Foundation for Dutch Scientific Research Institutes. The two bodies have the same executive/foundation-board members, but separate legal identities and employers. Current executive governance has six members. Ferdinand Grozema succeeded Jan de Boer as Science-domain chair on September 1, 2026, and Guda van Noort is an interim Social Sciences and Humanities chair. Research budgets and grant programmes are not represented as externally closed venture funds.

Anka Mulder is NWO’s vice president and executive-board portfolio holder for operations and finance. Before NWO she chaired Saxion University of Applied Sciences from 2018 and served as vice chair of Delft University of Technology’s executive board from 2013 to 2018. The official NWO directory also lists her chairmanship of Stichting Studielink and supervisory affiliation with Quantum Delta NL.

Marcel Levi is a physician and professor of medicine who has led the Dutch Research Council since April 2021. His second presidential term began April 1, 2026. He previously led Amsterdam Medical Center and University College London Hospitals and held academic leadership roles at the University of Amsterdam and University College London.

Onur Oztaskiran works in Design at Play Money. He has more than20 years of visual communication and product-design experience across finance, education, blockchain and AI. His employer biography describes product and growth work, and its team tagline identifies earlier founding-design work at Udemy and Writer.

Juliette Chevalier is Growth Engineer at Play Money. Her career includes software development, developer relations and Helicone AI. She co-founded Surge, a community for women in crypto, and Adult Camp for Latin American founders. Her own juliet.tech site corroborates the former-diplomat/software-engineer identity; the unrelated Dennis Aronov link on her employer card is excluded.

Melissa Eder works in Marketing at Play Money. She is a bilingual marketer, entrepreneur and community builder with marketing and operations experience for investment platforms, helping explain emerging technology and investing to wider audiences.

Tina Hashemnia leads Founder Success and Deal Flow at Play Money. Her employer biography describes prior venture-capital chief-of-staff work, accelerator operations across several cohorts and venture-scout experience supporting founders and fundraising.

Wasim Khamlichi leads Product and Engineering at Play Money and is described in the company’s own team tagline as founder and CTO. He built music marketplace Airbit through its acquisition and previously began his technical career at EDS. His background combines software engineering, creator marketplaces and music production.

Play Money is an early-stage angel-investment marketplace operated by Play Money Studios, Inc., as identified in its current terms. Founder and CEO Cheryl Kellond and a six-person public team operate a platform offering curated pre-seed and seed opportunities, investor education and transaction administration. Accredited investors participate through separate special-purpose vehicles; Play Money’s founder explains that these are series of its top-level Clutch Capital LLC, which appears on investee cap tables. The operating platform, legal SPV issuers and individual member portfolios are distinct. Play Money’s terms expressly disclaim investment-adviser or fiduciary capacity; this profile does not identify it as a registered pooled venture-fund adviser. Its platform-sponsored portfolio spans healthcare, AI diagnostics, gut–brain virtual care, rehabilitation, climate and software. Current member holdings corroborate SideBy Care, but the underlying company amount, date and stage are undisclosed. SEC initial notices identify Clutch Capital series vehicles and offering targets, including the SideBy Care SPV and Play Money I/II; reported zero sales are not completed cash closes. Founding2023 is stated in the platform’s own current publications. Member investments, dashboard illustrations, founder personal portfolio totals and aspirational capital goals are not treated as the platform’s paid cash or fund AUM. Verified legal-series filings include eleven sponsored vehicles. Three report fully sold SPV subscription proceeds: Dyme Medical USD52,899, Redwood USD100,000 and Series X USD423,500. Eight other initial notices, including SideBy Care and Play Money I/II, report zero sold; their targets are not fund closes. These are separate sponsored pooled issuers and their subscription proceeds are not automatically company financing.

Cheryl Kellond founded Play Money and serves as CEO. Her operating career includes early product launches, venture-backed startup building and a prior acquisition. Her own biography describes mentoring nearly200 founders and a personal angel portfolio of about50 companies; these are personal career figures rather than Play Money fund closes.

SaaSholic is an early-stage venture capital firm investing in Latin American B2B software, SaaS and AI-native companies with predictable or recurring business models. Founded by software operators, it backs founders from the earliest stages and provides practical support in enterprise sales, marketing, pricing, hiring, go-to-market execution and fundraising. Its concentrated portfolio includes AI identity-verification platform Didit, AI risk and credit decision software Sinky, agentic debt-recovery platform HiSofi, legal software Jusfy and enterprise governance company Atlas Governance. The firm began in2019 with an angel fund and has since built successive institutional vehicles for software founders serving Latin American and global markets.

With a background in entrepreneurship and deep experience in SaaS and VC, Diego's goal is help early stage startup CEOs to scale their businesses to global success.

Dotun is the General Partner at Ventures Platform, with extensive experience in entrepreneurship, investing, and C-level operations. His skill set includes venture investing, portfolio support, board management, startup fundraising, product development, innovation consulting, community building, local and remote team leadership, P&L oversight, and multichannel growth marketing for both startup and established organizations. Before joining Ventures Platform, Dotun served as Principal at Novastar Ventures Platform and Chief Commercial Officer at Moniepoint. In these roles, he provided leadership in fundraising, investor relations, strategic investment, and acquisition. Dotun has over 20 years of experience across various sectors, and as a Board Observer for Moniepoint, he worked with the company from 2021-2022 to establish its services as a leading financial technology provider for SMEs and consumers. He was also an Investor and Board Observer at Turaco from 2020-2021.

Elo is the Founder and CEO at Terragon Group, the leading DATA and Marketing Cloud company in Africa, which helps Brands intelligently deliver more meaningful experiences to African consumers on mobile. For over 13 years he has steered the company through its evolution from a digital agency to Africa’s foremost SaaS (Software as a Service) company; with development of proprietary, patented technology solutions, successful acquisition of a software company in Bangalore in 2018 and strategic partnerships with global technology and indigenous companies including Meta, Microsoft, MTN, Nigerian Breweries etc.

Ezinne is an experienced Executive Assistant and manages Investor Relations at Ventures Platform Fund. With over seven years of experience at the company, she has demonstrated excellent skills in schedule management, event coordination, and investor experience. Prior to joining Ventures Platform Fund, Ezinne worked as a program associate at the TY Danjuma Foundation, where she gained experience in Project Management and Coordination, managing several projects across Nigeria. She also worked as a Human Resource Manager at the Corporate Affairs Commission. Overall, she has developed strong communication, organisation, and project management skills, which have enabled her to excel in her roles at Ventures Platform Fund.

Gus has been working on scaling software sales teams and developing GTM for a long time, and his goal is to help our portfolio companies hire, scale and accelerate their revenue growth.

With over a decade of experience across fintech, global health, and social impact, Barry is a seasoned operator and strategist who brings rare depth and regional expertise to the firm. Her role will see her centrally placed in identifying and supporting transformative early-stage startups, particularly those building a low-carbon, inclusive, and prosperous future for the continent. Prior to joining Ventures Platform, Barry led business development in Francophone Africa for Taptap Send, one of the largest cross-border payment companies operating across Africa, Asia and Latin America. Through her leadership, the business achieved significant profitability through strategic partnerships. She also held pivotal roles at Zipline, where she negotiated national-level partnerships to expand access to essential health commodities.

Hafeez Bakare is published by Ventures Platform as Head, Finance and Fund Operations.

Ifeoma is an experienced Fund Operations Analyst, Growth Strategist, and Audit Analyst. She is currently working as a Fund Operations Analyst for Ventures Platform Fund, where she provides insight into fund operations procedures for prospective clients due diligence processes and retrieves and maintains records of portfolio statistics and other investment operations reporting for internal and external stakeholders. Ifeoma has also served as a Director of Growth and Strategy at Quayo Ecosense Limited, where she is responsible for defining the company's growth strategy, coordinating and executing growth plans, and optimizing the funnel to meet revenue targets.

Innocent Isichei is an accomplished policy professional with extensive experience working with stakeholders in both the public and private sectors across Africa. He currently serves as a Director at ACIOE Associates, where he assists clients in entering new markets in Africa. His role involves shaping policy discourse on critical issues, such as fostering the growth of the payment ecosystem in key African markets. Additionally, Innocent supports the regulatory and government engagement efforts of clients, enhancing their understanding of the policy environment in countries like Nigeria, Ghana, South Africa and Kenya. Innocent is also a Senior Policy Adviser to Paystack Payments and a Partner at Ventures Platform, one of Africa’s leading venture capital firms. He previously served as the Director of Policy for Paystack Payments, where he played a pivotal role in shaping the company’s strategic direction and regulatory compliance.

Kola is an established investor, insightful non-Executive director, and company chair who is passionate about seeing start-ups grow and improving the lives of ordinary Africans by democratising prosperity. He brings demonstrable success from leading investment in over 70 companies in Africa, India, and the US, including payments companies such as Paystack. He has established networks across the private sector, development partners, financiers, governments, and regulators.

Moyosoreoluwa is a highly skilled Executive Assistant, Virtual Assistant, and Administrative Manager with over six years of experience providing comprehensive support to executives and managing client-focused office operations. She is goal-oriented, results-driven, and recognized for her exceptional ability to streamline administrative processes, optimize productivity, and ensure seamless executive support.Currently serving as an Executive Assistant and Administrative Manager at Ventures Platform Fund, Moyosoreoluwa expertly manages executive schedules, event coordination, and high-level administrative functions. She is highly regarded for her adaptability and efficiency in handling dual responsibilities, ensuring smooth day-to-day operations.

Odunayo is an experienced accountant with over 7 years of professional experience in finance and accounting. She holds a BSc degree in Accounting from Wesley University in Ondo and is a chartered accountant with the Institute of Chartered Accountants of Nigeria (ICAN). Odunayo has a strong background in Budgeting, Financial planning and management, Financial reporting, Financial Analysis, and Accounting. She is detail-oriented, highly organized, and has excellent communication and analytical skills.

Oluwaseyi Tomosori is a corporate communications professional with 7 years of experience in driving reputation management and other strategic communication priorities for global brands and organizations. She is currently a Communications Associate within the Platform and Networks practice at Ventures Platform, where she leads the firm’s strategic communications efforts while also fostering a thriving community amongst its portfolio companies.

Sola is an investment analyst with extensive experience in fixed-income research, financial valuation, competitor research, investment deal execution, accounting, and auditing. She has worked at different companies, including FCSL Asset Management, MBO Capital Management Limited, Aircom Nigeria Limited, and Adcem Healthcare Ltd. Currently at Ventures Platform Fund, Sola is responsible for sourcing, evaluating, and executing deals. She conducts research on various investment, reviews and analyzes industry, company, and third-party research for the Active portfolio, and prepares presentations to the Investment Committee at VP Fund.

With years of expertise in M&A and Asset Management, Pedro is focused on supporting new investments and providing hands-on assistance to portfolio companies across key strategic and operational areas.

With previous buy-side experience in Private Equity and Equity Research, Vinícius brings an analytical approach to SaaSholic’s research and fundraising efforts, helping the firm deliver insights and connect capital to the region’s most promising SaaS founders.

According to our founders, William is their guardian angel. William focuses on leveraging his operational expertise and vast network to support our founders to bring home the capital they need.

Yassin leads deal sourcing and execution across North Africa. He brings experience across investment and technology, having previously worked at AfricInvest, Sequence Ventures, and Procter and Gamble. Earlier in his career, he founded Wasalny, an Egyptian mobility startup. Yassin holds a BEng with First-Class Honours in Mechanical Engineering from Coventry University.

Ventures Platform is a Pan-African venture capital firm backing founders building technology that expands access to essential products and services, lowers delivery costs and fills infrastructure gaps. It invests from pre-seed and seed to pre-Series A and supports selected companies through follow-on rounds. Its cross-sector portfolio spans payments, business software, health technology, agriculture, mobility and AI-enabled services. The firm combines capital with post-investment support in hiring, commercial growth, governance, networks and subsequent fundraising, including local expertise in Francophone and North African markets. Its published holdings include Moniepoint, PiggyVest, Raenest, Seamless Technologies and healthcare companies such as Reliance Health and Tanel; acquired payments business Paystack is a disclosed exit.

Adebimpe Popoola is a seasoned People, Culture and Operations leader with experience spanning technology, venture capital, professional services, workforce solutions and high-growth businesses. Her expertise cuts across people strategy, HR service delivery, organisational development, workforce planning, performance management, culture transformation and regional operations.

Telecoms and Fintech Executive with 12+ years of international experience, including 8 years in C-level roles leading growth, innovation, and transformation. As CEO of Orange Money Mali, Aicha led it to become Orange Group’s largest and top-performing financial institution. Previously, as the inaugural Chief Strategy and Innovation Officer at Orange Mali, she built and scaled a newly created department into a key decision-making hub.

Collins is a versatile and experienced professional with a passion for entrepreneurship and innovation. He has a diverse background, having worked with organisations such as Ventures Platform Foundation, Sail, Greativation Limited, and Dataville Research LLC. Currently, Collins serves as an Analyst at Ventures Platform Fund, where he builds the company's Portfolio Support platform to provide support to its portfolio companies at scale. He also supports the investment team in finding and funding mission-driven founders building exceptional solutions to some of Africa's biggest problems.

Damilola Teidi is an ecosystem builder with 10+ years experience in the technology space in Africa, with most of that time spent supporting and facilitating access to capital for high-growth technology startups across different stages of growth. Damilola is currently the Head of Platform and Networks at Ventures Platform, where she leads a team focused on building and ensuring the effective delivery of expertise-driven post-investment support initiatives that create value for the fund’s portfolio companies.

Desigan Chinniah, aka Dees or cyberdees, is a creative technologist. Dees has a portfolio of advisory roles and board positions. He invests early into diverse and underestimated minority founders.Dees has had two decades of dot-com check-ins*. His superpower is his global relationship network and the ability to embrace chaos and context switch in sub-50ms. Advisor: Cloaked + Interledger Foundation + TigerBeetle + Zama

Dolapo is an Investor at Ventures Platform. She is responsible for driving the investment process end-to-end including functions such as Deal Sourcing, Due Diligence, Transaction Structuring, and Portfolio Management. She currently serves on the board of Termii and as a board observer for SunFi. She is also a Mentor at Google for Startups. She spent 5+ years as a Strategy Consultant for Accenture and Bain working on transformational projects across multiple countries in the Middle East and Africa (e.g. Nigeria, Ghana, South Africa, Seychelles, Saudi Arabia, UAE) where she supported multiple government ministries and the largest multinational corporations across Energy, Finance, Agriculture, Consumer goods, Telecommunications and Mining.

His own current public professional profile identifies Singular as his employer.

Singular investor named by the 2026 How to Web conference.

Leads Singular communications and marketing; separately advises startup VIOLA.

Singular investor and its first employee; her own public posts verify current firm activity.

Supports European founders with go-to-market strategy and international growth.

Greg Yap is a life-science and healthcare investor named in Mission Bay Capital’s outside investment advisory committee. Menlo Ventures’ own current biography identifies him as partner focused on healthcare, novel therapeutic platforms and technology, having joined in2017. His earlier experience includes Illumina Ventures, startup founding, Roche diagnostics and Affymetrix. He studied molecular biology at Princeton and earned an MBA at Stanford. The Mission Bay affiliation is outside advice and does not establish a personal investment or fund employment.

Technology investor focused on developer tools, security and infrastructure.

London-based Singular investor.

Supports founder and talent connections for Singular.

Invests at the intersection of AI, life sciences and frontier innovation.

Finance professional at Singular; current self-profile confirms the employer but hides her exact title.

Life-sciences investment and commercialization specialist; previously worked at OurCrowd and Medison Ventures.

Singular co-founder; current own legal page names him its UK compliance officer.

Sources neuroscience companies and academic research in the United States.

Neuroscience scientist with experience in psychiatric drug development and medical-device regulation.

Supports neuroscience investment sourcing and diligence.

Leads Corundum Neuroscience’s lab-to-market venture-building and investment platform.

Creates science content for Corundum Corporation; published on the neuroscience group roster.

Singular co-founder and general partner, as identified by portfolio company Vibe.

Reviews neuroscience research and previously studied healthy aging.

Justin Merle, CPA, is an investor at Zebra Ventures. Zebra’s own2024 report identifies him as Tony Palcheck’s colleague in its corporate venture team; his current professional profile and own2026 Apera AI investment posts corroborate the ongoing affiliation. The named2023 industry profile records earlier EY strategy/transactions work; this prior career is qualified historical. His investing work includes automation, computer vision, industrial software and enterprise technologies.

Tony Palcheck is vice president of Zebra Ventures, as named in Zebra’s April29,2026 Apera AI investment announcement. Earlier own interviews describe his role leading the corporate venture portfolio after joining Zebra through the October2014 Motorola Solutions enterprise-business acquisition. Managing Director is a historically published title. His work spans enterprise automation, AI, analytics and strategic technology investing.

Zebra Ventures is the corporate venture capital arm of Zebra Technologies Corporation (NASDAQ: ZBRA), backing early-stage technology businesses relevant to industrial and enterprise operations. It focuses on automation, robotics, artificial intelligence, analytics, sensing and related technologies used in manufacturing, warehousing, logistics, retail and healthcare. The venture function took its current identity after Zebra’s October2014 acquisition of Motorola Solutions’ enterprise business, combining earlier Zebra investments with the transferred enterprise-oriented venture portfolio. Corporate investment professionals Tony Palcheck and Justin Merle are publicly identified by Zebra and corroborated by current issuer investment announcements and their own professional profiles. The arm provides strategic expertise, engineering access and commercial networks alongside investment capital. It is a corporate investing function rather than a separately verified external LP-backed fund; published target check ranges and portfolio asset values do not establish actual cash raised. Its primary portfolio includes Neurala, industrial robotics businesses and healthcare-workflow technology. It is distinct from Swiss Zebra Impact Ventures, UAE/Spanish firms using similar names, Zebra Medical Vision and insurance marketplace The Zebra.

Dongping Li (李東平/李东平) is the general-partner owner of TianjinHaifengYinhuaInvestmentManagementPartnership, the disclosed general partner of WenzhouHaiyin and TianjinHaiyin investment vehicles. The2025 HKEX issuer prospectus names him alongside YuquanWang, XiaomeiWu and XinMa as the manager’s four owners. This primary evidence establishes his legal management capacity within the Haiyin ownership network; it does not independently disclose his complete career history, current payroll title or education. Secondary romanisation DongpingLee is treated as a discovery alias, without merging unrelated similarly named investors.

Xiaomei Wu (吳曉梅/吴晓梅) is a limited-partner owner of TianjinHaifengYinhuaInvestmentManagementPartnership, which a2025 HKEX issuer prospectus identifies as the general partner of WenzhouHaiyin and TianjinHaiyin investment partnerships. She is named alongside DongpingLi, YuquanWang and XinMa in that exact manager ownership disclosure. The primary filing establishes her legal affiliation, while accessible current first-party sources do not independently establish a full biography, exact operating executive title or appointment date. Secondary databases describe a founding-partner role, which is retained as a research lead rather than imported as unqualified current employment.

Xin Ma (馬昕/马昕) is a Haiyin Capital partner explicitly quoted in Neurala’s primary June2016 financing announcement. He described the commercial opportunity for AI technology enabling autonomous consumer products and the firm’s connections with manufacturers and technology companies in China. Neurala publishes his original named portrait. A2025 HKEX prospectus identifies MaXin as a limited-partner owner of TianjinHaifengYinhua, the manager of two Haiyin investment vehicles. The recent legal ownership corroborates the exact investment-network identity, while his historical operating partner title is not asserted to be a fully updated2026 employment roster.

Yuquan Wang (王煜全) is the founding partner of Haiyin Capital and chair of InnovationMap, according to his primary speaker biography and the affiliated company’s own published history. He founded Haiyin in2008, connecting technology investment with manufacturing and commercialisation between the UnitedStates and China. His professional biography describes earlier founding roles at Consultech in1995 and the China subsidiary of Frost&Sullivan in1998. His published education and industry commentary span science and global innovation. A2025 HKEX prospectus also identifies him as a limited-partner owner of TianjinHaifengYinhua, the general partner of WenzhouHaiyin and TianjinHaiyin investment vehicles. This ownership is distinct from personal financing checks.

Haiyin Capital (海银资本) is a Beijing-based technology venture-investment platform founded in2008 by Yuquan Wang. Primary founder and affiliated InnovationMap biographies describe a strategy connecting US technological innovation with Chinese manufacturing, commercialisation and markets, with interests in AI, robotics, electronics, aerospace, healthcare and energy. Neurala’s original June2,2016 issuer announcement identifies Haiyin as a co-lead of a completed USD1.2million follow-on financing and names partner Xin Ma. A2025 HKEX issuer prospectus identifies WenzhouHaiyin and TianjinHaiyin investment partnerships, managed by TianjinHaifengYinhuaInvestmentManagementPartnership(LP), whose owners are DongpingLi, YuquanWang, XiaomeiWu and XinMa. This legal vehicle disclosure supports the ownership network but does not make the manager, all funds and the Haiyin brand interchangeable legal subscribers. Fund sizes and cash closes are not disclosed in that evidence. Haiyin is distinct from ShanghaiHaiyin wealth-management/fund-sales companies, GuangzhouHaiyin industrial entities and HaierCapital. The historical haiyincapital.com domain now serves unrelated gambling content and is excluded as a current official source. Authentic historical branding and XinMa’s original portrait are independently preserved in Neurala’s primary investor release; current operating roster and replacement official manager website remain partially undisclosed.

Christopher Porter PhD is a published external PureTech collaborator and director of the Monash Institute of Pharmaceutical Sciences in Australia. PureTech’s Glyph platform links identify lymphatic drug-delivery research; no corporate employment is inferred.

Maryanne Senna MD is a published external PureTech collaborator, a dermatologist at Massachusetts General Hospital and an assistant professor at Harvard Medical School. PureTech identifies her as founder and co-director of the MGH Hair Loss Clinic.

Samantha Meltzer-Brody MD is a published external PureTech scientific collaborator and the Assad Meymandi distinguished professor and psychiatry chair at UNC Chapel Hill. The affiliation does not establish a corporate board role or individual investment.

Daniel Wheeland is named in the current NIH associate-director directory as Associate Director for Research Facilities. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Jane Simoni is named in the current NIH associate-director directory as Associate Director for Behavioral and Social Sciences Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Michael A. Rogawski MD PhD is a published external PureTech scientific collaborator and professor of neurology and pharmacology at UC Davis. The academic neuroscience affiliation is recorded separately from corporate employment or board membership.

Neil Shapiro is named in the current NIH associate-director directory as Associate Director for Budget. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Phillip Osborne is named in the current NIH associate-director directory as Acting Associate Director for Administration. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Steven Paul MD is a published external PureTech scientific collaborator. PureTech identifies him as founder and board chair of Seaport Therapeutics. This supports the neuroscience affiliation without implying a PureTech directorship or individual investment. Seaport’s own biography identifies more than40years in neuroscience and molecular neuropharmacology, prior KarunaCEO/chair and research leadership,17years at EliLilly including president of LillyResearchLaboratories, and18years at NIH including scientific director of NIMH.

Marlies Wijsenbeek is a published external PureTech collaborator and chair of the Erasmus Medical Center interstitial lung disease program. PureTech identifies her as principal investigator of a study of disease progression in newly diagnosed progressive fibrosing interstitial lung disease.

Paul Noble is a published external PureTech collaborator and chair of medicine at Cedars-Sinai. PureTech highlights his work on two late-stage pirfenidone trials in idiopathic pulmonary fibrosis. No corporate employment or investment is inferred.

Peter Kilmarx is named in the current NIH associate-director directory as Acting Director for International Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Renate Myles is named in the current NIH associate-director directory as Associate Director for Communications and Public Liaison. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Colleen McGowan is named in the current NIH associate-director directory as Associate Director for Research Services. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Katherine Klimczak is named in the current NIH associate-director directory as Associate Director for Legislative Policy and Analysis. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Kevin Flaherty is a published external PureTech collaborator and University of Michigan professor. PureTech highlights his work on the Phase III nintedanib trial in progressive fibrosing interstitial lung disease, published in NEJM. No employment or personal investment is inferred.

Sean Mooney is named in the current NIH associate-director directory as Associate Director for Information Technology, Cyberinfrastructure and Cybersecurity. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Toby Maher is a published external PureTech collaborator and professor and director of interstitial lung disease at USC Keck School of Medicine. PureTech highlights his Phase II pirfenidone trial in unclassifiable interstitial lung disease. This is an external scientific affiliation.

Bill Bradford is a published external scientific collaborator of PureTech and its Founded Entities. The company identifies him as a former InterMune senior vice president who developed pirfenidone for idiopathic pulmonary fibrosis. This affiliation does not establish PureTech employment or a personal investment.

Geri Donenberg is named in the current NIH associate-director directory as Associate Director for AIDS Research. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Janine Clayton is named in the current NIH associate-director directory as Associate Director for Research on Women's Health. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Lyric Jorgenson is named in the current NIH associate-director directory as Associate Director for Science Policy. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Susan Gregurick is named in the current NIH associate-director directory as Associate Director for Data Science. This institutional leadership affiliation is distinct from private venture investing or personal company ownership.

Vincent Cottin is a published external PureTech collaborator, professor at Université Claude Bernard Lyon and coordinator of rare pulmonary diseases at Louis Pradel Hospital. The company also identifies his editorial role at the European Respiratory Journal. This is an external research affiliation.

H. Robert Horvitz PhD is PureTech’s board observer, R&D Committee chair and external scientific collaborator. A Nobel laureate, he is an MIT biology professor, HHMI investigator and MGH neurobiologist. His company founding includes Epizyme, Mitobridge and Idun; the observer role is distinct from a board directorship. Gates Foundation scientific advisory biography: H. Robert Horvitz, Ph.D. Robert Horvitz shared the Nobel Prize in Physiology or Medicine in 2002. He is the David H. Koch Professor of Biology at the Massachusetts Institute of Technology (MIT), an investigator of the Howard Hughes Medical Institute, neurobiologist (neurology) at the Massachusetts General Hospital, a member of the MIT McGovern Institute for Brain Research, and a member of the MIT Koch Institute for Integrative Cancer Research. Horvitz’s research, focused on the roundworm C. elegans, has helped define evolutionarily conserved molecular genetic pathways important in human biology and human disease, including a major cancer-gene pathway and the pathway responsible for programmed cell death, or apoptosis. He has received many honors and awards. Horvitz is a member of the board of trustees of the Massachusetts General Hospital and is chairman of the board of trustees of the Society for Science and the Public. He was president of the Genetics Society of America. He has served on many editorial boards, visiting committees, and advisory committees. Horvitz was an advisor adviser to the WHO Special Programme for Research and Training in Tropical Diseases. He was co-chair of the National Cancer Institute Working Group on Preclinical Models for Cancer, and a member of the National Human Genome Research Institute Advisory Council, the U.S. National Academies of Science and Institute of Medicine Committee on Guidelines for Human Embryonic Stem Cell Research, and the American Academy of Arts and Sciences Committee on Advancing Research in Science and Engineering. He also was a member of the advisory committee to the director of the National Institutes of Health, and he was a member of the council of the U.S. National Academy of Medicine. Horvitz has been a consultant to pharmaceutical, biotechnology, and venture capital companies.

Robert F. Kennedy Jr. is named by the National Institute on Drug Abuse as Ex officio, National Advisory Council on Drug Abuse (HHS Secretary). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Glenn A. Tapia is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Kiran Mazumdar-Shaw is PureTech’s independent non-executive director and the founder of Biocon. Her published biography identifies MIT trusteeship, National Academy of Engineering membership and roles at Infosys and Narayana Health. She studied zoology at Bangalore University and malting and brewing in Australia and received the Padma Shri and Padma Bhushan.

Mark E. Von Zastrow is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Angela R. Laird is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

John LaMattina PhD is PureTech’s independent non-executive director, serving since 2009. He previously led Pfizer Global Research and Development during a 30-year Pfizer career and is a pharmaceutical research author. He studied chemistry at Boston College and the University of New Hampshire and conducted NIH postdoctoral research at Princeton.

Kevin Gray is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Cristiane S. Duarte is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Michele Holcomb PhD is PureTech’s independent non-executive director and Audit Committee member. Her healthcare strategy career includes leadership at Cardinal Health, Teva and McKinsey. She holds chemistry degrees from Stanford and Berkeley and previously worked as a research chemist at Ciba-Geigy and Syntex.

Sandra D. Comer is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Allison Mead Talbot is PureTech’s senior vice president of communications, responsible for corporate and internal communications and investor and media relations. Before joining in 2016 she worked at TogoRun/FleishmanHillard and Feinstein Kean Healthcare/Ogilvy. Her experience includes regulatory launches, transaction communications and corporate branding.

Arpana Agrawal is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Deborah Chassler is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Ivan Montoya is named by the National Institute on Drug Abuse as Acting Director, Division of Therapeutics and Medical Consequences. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Katherine L. Beebe Devarney is named by the National Institute on Drug Abuse as Member, National Advisory Council on Drug Abuse (external adviser). This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Sharon Barber-Lui is PureTech’s published interim board chair and Audit Committee member. Her finance career includes Teva’s North America CFO role, EQRx and more than 20 years at Merck, after starting at KPMG. She earned undergraduate and MBA degrees at Lehigh and is an AICPA member.

Charles (Chip) Sherwood JD is PureTech’s chief operating officer and general counsel, overseeing strategy, operations, governance and compliance. He joined in August 2021 after leading corporate legal work at Anika Therapeutics. He earned degrees at Middlebury and Vanderbilt and is admitted to the Massachusetts Bar.

Susan R. B. Weiss is named by the National Institute on Drug Abuse as Director, Division of Extramural Research; Executive Secretary, NACDA. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Tristan McClure-Begley is named by the National Institute on Drug Abuse as Acting Director, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Angela Lee-Winn is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Candace Webb is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Epidemiology, Services and Prevention Research. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.

Da-Yu Wu is named by the National Institute on Drug Abuse as HIV/AIDS research programme contact, Division of Neuroscience and Behavior. This public institutional affiliation supports biomedical research and does not establish a personal investment, company ownership, or a grant allocation.